Teva Pharmaceutical Industries Limited
TEVJF
$16.11
$2.3116.74%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.99% | -2.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.99% | -2.38% | |||
| Cost of Revenue | -4.50% | -3.39% | |||
| Gross Profit | -11.46% | -1.35% | |||
| SG&A Expenses | -3.47% | 3.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -92.86% | 247.37% | |||
| Total Operating Expenses | -4.62% | 0.24% | |||
| Operating Income | -20.60% | -11.06% | |||
| Income Before Tax | 219.03% | 23.05% | |||
| Income Tax Expenses | 164.29% | -59.42% | |||
| Earnings from Continuing Operations | 180.00% | 29.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -110.34% | 223.40% | |||
| Net Income | 198.62% | 50.34% | |||
| EBIT | -20.60% | -11.06% | |||
| EBITDA | -17.99% | -8.00% | |||
| EPS Basic | 198.17% | 50.35% | |||
| Normalized Basic EPS | -38.75% | 16.89% | |||
| EPS Diluted | 193.99% | 50.90% | |||
| Normalized Diluted EPS | -39.86% | 16.89% | |||
| Average Basic Shares Outstanding | 0.44% | 0.00% | |||
| Average Diluted Shares Outstanding | 2.29% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||